In this review, we will discuss the most recent advances in gene editing with respect to both the development of human-relevant disease models of CF as well as proof of concept studies that have shown the feasibility and safety of correcting a variety of CFTR mutations. This evidence concerns the gene CFTR and cystic fibrosis.